Stay updated on Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial

Sign up to get notified when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The footer now identifies the site as revision v3.8.0 instead of v3.7.2, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-04T01:07:38.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition from the term “artificial intelligence” to “super intelligence.” The site revision label changes from v3.7.1 to v3.7.2 while the study page continues to show a 403 error.
    Difference
    1%
    Check dated 2026-10-21T01:00:19.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    The footer’s site revision number changed from v3.7.0 to v3.7.1; the page still displays a 403 error.
    Difference
    0.2%
    Check dated 2026-10-07T01:07:22.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    403 Forbidden error page is shown instead of the study content. This indicates restricted access to the study record rather than displaying its details.
    Difference
    17%
    Check dated 2026-09-23T01:11:08.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page's revision marker updated from v3.6.6 to v3.7.0, indicating a minor update to the page version.
    Difference
    0.0%
    Check dated 2026-09-16T00:22:48.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The Belo Horizonte recruitment site is updated to Freire Pesquisa Clinica at 30150-320, replacing the previous listing at 30150-221 (Santa Casa de Misericordia). The study arms are clarified to include fenebrutinib with an ocrelizumab-matching placebo and vice versa, and Time to Onset of Composite 12-Week Confirmed Disability Progression (cCDP12) is added as an outcome, along with related administrative Certification/Extension entries.
    Difference
    0.3%
    Check dated 2026-09-08T22:50:15.000Z thumbnail image

Stay in the know with updates to Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fenebrutinib vs Ocrelizumab in Primary Progressive MS Clinical Trial page.